Eli Lilly and Company

LLY - How to handle earnings

75
LLY reports this Thursday. The drop in early March to test the bottom of the uptrend was a great opportunity. Now it's at all time high, showing bearish divergence, and has a history of price reversals after earnings releases.

I'll be looking for updates on their pipeline management, monjaro production and growth, and progress toward Alzheimer treatment. The latter is high potential, but clinical trials in that space fail regularly.

I'll likely take a little profit before earnings and then re-accumulate to pullbacks to the 347-356 range.

免责声明

这些信息和出版物并不意味着也不构成TradingView提供或认可的金融、投资、交易或其它类型的建议或背书。请在使用条款阅读更多信息。